Following the announcement of the end of the Ebola virus disease (EVD) outbreak in the Democratic Republic of Congo (DRC) on 24 July 2018 (see WHO press release: http://www.who.int/news-room/detail/24-07-2018-ebola-outbreak-in-drc-ends-who-calls-for-international-efforts-to-stop-other-deadly-outbreaks-in-the-country), the Health Ministry of the DRC announced a second outbreak of EVD within its borders on 1 August 2018 (see WHO website: http://www.who.int/ebola/en/ and http://apps.who.int/iris/bitstream/handle/10665/273867/SITREP_EVD_DRC_20180814-eng.pdf?ua=1).

At 18 August, total of 91 cases of hemorrhagic fever have been identified, of which 50 had a fatal outcome. Laboratory testing confirmed EVD for 64 of the cases investigated, with 27 cases remaining probable (i.e. not confirmed). The numbers of cases will continue to fluctuate in coming days as the investigation continues to confirm and discount cases. The cases have been reported from the health zones of the North Kivu and Ituri Provinces, located towards the eastern border of the DRC. This is a remote and conflicted location in the DRC, located more than 3000 Km from the capitol Kinshasa (https://www.afro.who.int/news/who-calls-free-and-secure-access-responding-ebola-outbreak-democratic-republic-congo). Containment efforts, including vaccination and strengthening of cross-border surveillance, have been mobilized (http://apps.who.int/iris/bitstream/handle/10665/273867/SITREP_EVD_DRC_20180814-eng.pdf?ua=1).

Genomic sequencing analysis of outbreak samples have indicated the involvement of the Ebola virus Zaire strain in this outbreak. The previous outbreak in the Equateur Province also involved the Zaire strain, but the two outbreaks are unrelated.

WHO advises against any restriction of travel and trade to the Democratic Republic of the Congo based on the currently available information. WHO continues to monitor travel and trade measures in relation to this event. The regulations for evidence of a valid yellow fever vaccination certificate apply. Precautions against malaria should be applied as per routine practice. Malaria must be considered a high priority in the investigation and management of any febrile traveler.

Follow these links to read more about EVD:

National Institute for Communicable Diseases: http://www.nicd.ac.za/index.php/ebola-virus-disease/

World Health Organization, Ebola virus disease webpage: http://www.who.int/ebola/en/.